Last reviewed · How we verify
Red blood cells
At a glance
| Generic name | Red blood cells |
|---|---|
| Also known as | RBCs |
| Sponsor | McMaster University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
- Blood Pool Imaging
- Detection of Gastrointestinal Bleeding
Common side effects
Key clinical trials
- Treatment of Hemochromatosis (PHASE2)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (PHASE3)
- Photo-Acoustic and Ultrasonographic Mammoscope (PHASE2)
- A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (PHASE2)
- Mechanisms Accounting for Unexplained Anemia in the Elderly (PHASE1)
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
- Platelet Rich Plasma for Musculoskeletal Conditions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Red blood cells CI brief — competitive landscape report
- Red blood cells updates RSS · CI watch RSS
- McMaster University portfolio CI